Last reviewed · How we verify

NCT05241912

Supernormal Oxygen Delivery for Patients With Severe Burns

Status unknown EARLY_PHASE1 Last updated 16 February 2022
What this trial tests

EARLY_PHASE1 trial testing Dobutamine in Burn Surgery in 100 participants. Status unknown.

Timeline
28 February 2022
Primary endpoint
1 June 2023
1 June 2023

Quick facts

Lead sponsorGuangzhou Red Cross Hospital
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment100
Start date28 February 2022
Primary completion1 June 2023
Estimated completion1 June 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangzhou Red Cross Hospital

Who can join

Adults 18 to 60, any sex, with Burn Surgery or Dobutamine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized double-blinded study to investigate in which the groups are designated as the control group and the goal-directed fluid therapy group to further evaluate significant differences in rate of complications during burn surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dobutamine

Trials testing the same drug.

Other Guangzhou Red Cross Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05241912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing